The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001812:Blood-Brain Barrier; D002540:Cerebral Cortex / Q000378:metabolism; D002746:Chlorpromazine / Q000009:adverse effects; D004298:Dopamine / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D004361:Drug Tolerance; D005260:Female; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D007031:Hypothalamus / Q000378:metabolism; D008032:Limbic System / Q000378:metabolism; D008297:Male; D010302:Parkinson Disease, Secondary / Q000097:blood / Q000139:chemically induced; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects; D012559:Schizophrenia / Q000378:metabolism* / Q000503:physiopathology; D009435:Synaptic Transmission; D013847:Thiethylperazine / Q000494:pharmacology
D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D013847:Thiethylperazine; D011388:Prolactin; D006220:Haloperidol; D002746:Chlorpromazine; D004298:Dopamine